Modified albumin–bilirubin grade to predict eligibility for second-line therapies at progression on sorafenib therapy in hepatocellular carcinoma patients
この論文をさがす
収録刊行物
-
- International Journal of Clinical Oncology
-
International Journal of Clinical Oncology 26 (5), 922-932, 2021-03-17
Springer Science and Business Media LLC
- Tweet
詳細情報 詳細情報について
-
- CRID
- 1360290617674228864
-
- ISSN
- 14377772
- 13419625
-
- データソース種別
-
- Crossref
- KAKEN